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Abstract: Urea cycle disorders (UCD), are genetically inherited diseases that may have a poor outcome
due to to profound hyperammonemia. We report the case of a baby girl diagnosed as N-acetylglutamate
synthase (NAGS) deficiency. The patient was evaluated due to diminished sucking and hypotonicity.
Physical examination showed hepatomegaly. Complete blood count, biochemical values and blood gas
analyses were normal, acute phase reactants were negative. Further laboratory analyses showed no
ketones in blood and highly elevated ammonia. Metabolic tests were inconclusive. Emergency treatment
was initiated immediately and she was discharged on the 15th day of admission. NAGS deficiency was
confirmed by DNA-analysis. She is now without any dietary restriction or other medication, except N-
carbamylglutamate (NCG). NAGS deficiency is the only UCD which can be specifically and effectively
treated by NCG. Early recognition of disease will lead to early treatment that may prohibit devastating
effects of hyperammonemia.
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ABSTRACT
Urea cycle disorders (UCD), are genetically inherited 
diseases that may have a poor outcome due to to profound 
hyperammonemia. We report the case of a baby girl diagnosed 
as N-acetylglutamate synthase (NAGS) deficiency. The patient 
was evaluated due to diminished sucking and hypotonicity. 
Physical examination showed hepatomegaly. Complete blood 
count, biochemical values and blood gas analyses were normal, 
acute phase reactants were negative. Further laboratory analyses 
showed no ketones in blood and highly elevated ammonia. 
Metabolic tests were inconclusive. Emergency treatment was 
initiated immediately and she was discharged on the 15th day of 
admission. NAGS deficiency was confirmed by DNA-analysis. 
She is now without any dietary restriction or other medication, 
except N-carbamylglutamate (NCG). NAGS deficiency is the 
only UCD which can be specifically and effectively treated by 
NCG. Early recognition of disease will lead to early treatment 
that may prohibit devastating effects of hyperammonemia.
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deficiency, hyperammonemia. 
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INTRODUCTION
Urea cycle disorders (UCD), caused by the 
deficiencies of enzymes or transporters involved 
in the urea cycle, are genetically inherited inborn 
errros of metabolism (IEM) that have variable 
clinical presentations. Severe deficiencies of 
enzymes are typically associated with profound 
hyperammonemia, presenting with poor feeding, 
vomiting, lethargy, tachypnea, convulsions, and 
coma, especially in the neonatal period. In milder 
deficiencies, catabolic circumstances such as 
illnesses or stress may trigger hyperammonemia 
and can present at any age. Neonatal UCDs 
are mostly misdiagnosed as neonatal sepsis. 
Children and adults with partial deficiencies 
can also develop neurological or psychiatric 
symptoms including headaches, behavioral 
changes, confusion, and cyclic vomiting.1
N-acetylglutamate synthase (NAGS) is one 
of the enzymes involved in the urea cycle that 
catalyses the production of N-acetylglutamate 
(NAG) from glutamate and acetyl-CoA. NAGS 
deficiency is probably the rarest UCD, with just 
over 50 published cases worldwide.2 It is most 
effectively treated with N-carbamylglutamate 
(NCG) that corrects hyperammonemia and 
support ureagenesis.3 
We report the case of a neonate diagnosed as 
NAGS deficiency.
Case description
A baby girl born at term weighing 2500 grams 
was evaluated in an external clinic on the fifth 
postnatal day due to diminished sucking and 
hypotonicity. She was the first living child of 
consanguinous parents (first degree cousins) 
of Turkish origin. Their first child had died 
suddenly at the age of 2 days due to unknown 
etiology. Early neonatal sepsis was the suspected 
diagnosis in the present child and she was 
admitted to the newborn intensive care unit. 
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Complete blood count, routine biochemical 
values and blood gas analyses were normal, acute 
phase reactants were negative. She was hydrated 
intravenously and to exclude meningitis, lumbar 
puncture was performed that showed normal 
microscopical and biochemical cerebrospinal fluid 
(CSF) values. Parenteral antibiotics were initiated. 
Since her general condition did not improve after 
rehydration, further laboratory analyses were 
performed that showed no ketones in blood but 
highly elevated ammonia (937 µmol/L, normal 
value <150 µmol/L). With the suspicion of an 
inborn error of metabolism, she was referred to 
our center on the 10th postnatal day.
Upon admission, she was in poor condition 
and was ventilated. Her weight and height were 
within low-normal centiles. Physical examination 
s h o w e d  h e p a t o m e g a l y  ( l i v e r  w a s  4  c m 
palpable below the lower costal margin). Initial 
laboratory analyses showed hyperammonemia 
(2404 µmol/L) and abnormal blood coagulation 
parametres. 
Ammonia  lower ing  agents  inc luding 
intravenous sodium benzoate 250 mg/kg as a 
bolus and NCG by nasogastric tube was initiated. 
Since the patient did not have a specific diagnosis, 
oral L-carnitine and biotin plus intramuscular 
hydroxycobalamin were administered according 
to the latest  guidelines on treatment for 
hyperammonemia.3
Brain MRI was performed that showed 
increased signal intensity of the caudate nucleus 
and putamen and insular cortex bilaterally 
(Figure 1).
Metabolic tests performed showed a normal 
acylcarnitine profile in dried blood spot analysis. 
Amino acids in plasma showed slightly increased 
alanine (496 µmol/L; NR: 143-439), normal 
glutamine (363 µmol/L; NR: 246-1182) and 
arginine (54 µmol/L; NR: 12-133) and decreased 
citrulline (2µmol/L; NR: 3-35). Urine amino acid 
analyses and urine organic acids were normal. 
Biotinidase activity was within normal limits. 
Thus, mainly a proximal UCD, either of NAGS 
or carbamoyl phosphate synthetase 1 (CPS1) 
deficiency, were suspected primarily due to 
inconclusive findings in acylcarnitine and amino 
acid analyses. She was discharged on the 15th day 
Figure 1. Brain MRI, axial plane FLAIR sequence (a) demonstrates increased signal intensity of the caudate nucleus and 
putamen (white arrows) and insular cortex (black arrows) bilaterally.  Note the signal abnormality is extending superiorly 
into the perirolandic regions (white arrows) and prefrontal cortex bilaterally (b). Axial plane T2-weighted MRI (c) shows 
T2 shortening of the putamen, globus pallidus and ventrolateral thalamus (white arrows) with decreased size. Axial 
apparent diffusion coefficient (d) magnetic resonance image shows restricted diffusion in the putamen and thalamus (white 
arrows) seen as dark signal
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of admission with protein limited diet, sodium 
benzoate 250 mg/kg per day and NCG 50 mg/kg 
per day. 
NAGS deficiency was confirmed by DNA-
analysis, which identified a known homozygous 
missense c.1450T>C (p.Trp484arg) mutation in 
exon 6 of the NAGS gene. Parents were shown to 
be heterozygous carriers of the mutation. 
After gradual decrease of the medical 
treatment except NCG (30 mg/kg per day), 
she is without any dietary restriction or other 
medication. She is now 1,5 years old with some 
degree of global retardation but improving 
milestones, without any further episodes of 
hyperammonemia since the inititation of NCG.
DISCUSSION
N A G S  d e f i c i e n c y  i s  t h e  r a r e s t  U C D , 
accounting for 0 ,5-1 % of  al l  UCDs,  that 
may have serious effects on the neurological 
s y s t e m  o f  t h e  n e w b o r n  d u e  t o  s e v e r e 
hyperammonemia  depending on the duration 
and degree of hyperammonemia.1-3 Prognosis 
is known to be unfavourable if ammonia levels 
exceed 1000 µmol/L.3 Differential diagnosis 
includes other IEMs (e.g. organic acidurias), 
and conditions that cause hyperammonemia 
(e.g. sepsis, liver failure, congenital infections, 
exogenous intoxications, certain drugs, porto-
caval shunting, Reye syndrome, conditions with 
protein catabolism, and excessive nitrogen supply 
due to parenteral nutrition). Premature infants 
can have transient hyperammonemia due to 
ductus venosus shunting of portal blood.3
D u e  t o  t h e  d e v a s t a t i n g  e f f e c t s  o f 
hyperammonemia, treatment including cessation 
of protein intake, continuous infusion of high 
dose parenteral glucose and nitrogen scavenger 
drugs should be started immediately. Drugs that 
can be used to treat hyperammonemia depending 
on the underlying etiology are nitrogen scavenger 
drugs (sodium benzoate, sodium phenylbutyrate, 
sodium phenylacetate), L-arginine and NCG. 
Another long term treatment option for UCDs is 
liver transplantation in selected patients. NCG 
is a synthetic drug and a structural analog of 
human NAG.3 Hyperammonemia due to NAGS 
deficiency can be effectively treated by NCG, 
and no dietary restriction may be needed, at least 
outside catabolic situations.4,5 NCG has been 
suggested to be added to the standard treatment 
protocol of hyperammonemia together with 
sodium benzoate, sodium phenylbutyrate and 
L-arginine.3
Genetic analysis is the gold standard for 
diagnosis of NAGS deficiency,3 since ordinary 
metabolic screening tests may be inconclusive. 
NAGS gene is located on chromosome 17 within 
band 17q21.31. At least 45 different mutations 
of NAGS gene have been described until now.2,6 
Al Kaabi et al. has reviewed the clinical and 
molecular spectrum of 41 different NAGS 
mutations showing 60 % to be missense, 10 % 
nonsense, 20 % frameshift and 10 % splice site 
mutations.6 The mutation of our patient is a 
previously known missense mutation, that is 
known to cause neonatal hyperammonemic 
crises.2,5,7 Genetic diagnosis should be performed 
to confirm the disease and also to provide 
prenatal testing and preimplantation genetic 
diagnosis (PGD) for the future offsprings of 
parents.
Our patient is now 1.5 year old with delayed 
motor and mental milestones. Hyperammonemia 
treatment was started on a relatively late period 
(the 10th day of life) when the catastrophic effects 
of hyperammonemia should have already begun. 
Reigstad et al.,8 have reported a baby girl with 
severe hyperammonemia (2235 µmol/L) that 
turned out to be due to NAGS deficiency, in 
whom NCG was started on the 4th day of life 
that showed normal neurological outcome later 
on. In our patient, after the initiation of NCG, 
no more hyperammonemic episodes have been 
observed, and no dietary restriction is needed 
now. Although NCG has prevented further 
mental deterioration, our case is an example of 
the undesirable effects of hyperammonemia in 
case of delayed diagnosis and treatment, and we 
would like to emphasize the need of immediate 
assessment of hyperammonemia and inititation 
of emergency treatment with nitrogen scavenger 
drugs and NCG. 
We would like emphasize the importance of 
metabolic screening (including ammonium levels) 
in ill neonates with septic findings. Pediatricians 
should be aware of the signs of intoxication type 
IEMs, since this type of metabolic disorders may 
be effectively treated with certain measures, 
if the diagnosis is made at the early time. A 
detailed history should be obtained from parents, 
especially the history of inbreeding and death 
of sibling should be questioned, since these 
items may suggest an underlying IEM. Family 
counselling should be assured for parents with 
an unexplained history of child death, since these 
parents may require PGD.
In conclusion, NAGS deficiency is the only 
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disorder within the urea cycle which can be 
specifically and effectively treated by NCG 
with no dietary restrictions. Early recognition 
of disease will lead to early treatment that may 
prohibit devastating effects of hyperammonemia 
and may affect disease outcome positively. n
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